Darinaparsin

DB06179InvestigationalSmall molecule

Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), solid tumors, multiple myeloma, and liver cancer.

Mechanism: Pharmacologically active on Tubulin
Curator reviewed
Primary indication: Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), solid tumors, multiple myeloma, and liver cancer.Curator reviewed
Formula / weight: C₁₂H₂₂AsN₃O₆S · 411.3 g/mol (avg)
Code names: ZIO-101

Resolves to

Compound

UNII9XX54M675GCAS69819-86-9ChEMBLCHEMBL3247378ChEBI94295

Clinical / RWD

ATCL01XX82

Structure

InChIKeyJGDXFQORBMPJGR-YUMQZZPRSA-NSMILESC[As](C)SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 5 drug categories

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Darinaparsin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account